Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Lucia MasarovaJorge E CortesKeyur P PatelSusan O'BrienGraciela M Nogueras-GonzalezMarina KonoplevaSrdan VerstovsekGuillermo Garcia ManeroAlessandra FerrajoliTapan Mahendra KadiaFarhad Ravandi-KashaniGautam BorthakurSara DellaSalaZeev EstrovElias J Jabbour Hagop M Kantarjian

Published in: Cancer (2020)

The current data confirm the long-term efficacy of nilotinib 400 mg twice daily in patients with CP-CML. A majority of patients can achieve sustained MR4.5.

Keyphrases

chronic myeloid leukemia
newly diagnosed
end stage renal disease
ejection fraction
physical activity
prognostic factors
magnetic resonance
electronic health record
big data
computed tomography
data analysis
patient reported